Replimune Group, Inc. (REPL) — 8-K Filings

8-K Filings (24)

• Replimune Group Files 8-K on Financials — Nov 6, 2025 Risk: low
  Replimune Group, Inc. filed an 8-K on November 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Replimune Group Files 8-K — Oct 20, 2025 Risk: low
  Replimune Group, Inc. filed an 8-K on October 20, 2025, reporting on other events and financial statements. The filing details the company's principal executive
• Replimune to Acquire Remaining Shares — Sep 18, 2025 Risk: medium
  Replimune Group, Inc. announced on September 16, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of the company not alre
• Replimune Group Files 8-K on Shareholder Votes and Disclosures — Sep 4, 2025 Risk: low
  Replimune Group, Inc. filed an 8-K on September 4, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial
• Replimune Group Files 8-K on Financials — Aug 7, 2025 Risk: low
  Replimune Group, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements a
• Replimune Group Files 8-K — Jul 22, 2025 Risk: low
  Replimune Group, Inc. filed an 8-K on July 22, 2025, reporting on events that occurred on July 21, 2025. The filing indicates disclosures related to Regulation
• Replimune Group Files 8-K for Regulation FD Disclosure — Jun 24, 2025 Risk: low
  On June 24, 2025, Replimune Group, Inc. filed an 8-K report. The filing indicates that the company is providing a Regulation FD Disclosure. No specific financia
• Replimune Group Files 8-K on Operations — May 22, 2025 Risk: low
  Replimune Group, Inc. filed an 8-K on May 22, 2025, reporting on its results of operations and financial condition. The filing details financial statements and
• Replimune Announces Executive and Board Changes — Mar 7, 2025 Risk: medium
  Replimune Group, Inc. announced on March 5, 2025, the departure of Dr. Robert L. Kirk as Chief Medical Officer and the appointment of Dr. Philip J. Kantoff as i
• Replimune Group Files 8-K on Financials — Feb 12, 2025 Risk: low
  Replimune Group, Inc. filed an 8-K on February 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
• Replimune Group Files 8-K — Jan 22, 2025 Risk: low
  Replimune Group, Inc. filed an 8-K on January 22, 2025, reporting other events and financial statements/exhibits. The filing date indicates the earliest event r
• Replimune Group Files 8-K — Nov 27, 2024 Risk: low
  Replimune Group, Inc. filed an 8-K on November 27, 2024, reporting other events and financial statements. The filing date for the report was November 25, 2024.
• Replimune Strikes $1.85B+ Oncology Deal — Nov 26, 2024 Risk: medium
  Replimune Group, Inc. announced on November 25, 2024, that it has entered into a strategic collaboration with a major pharmaceutical company. This collaboration
• Replimune Group Files 8-K — Nov 21, 2024 Risk: low
  Replimune Group, Inc. filed an 8-K on November 21, 2024, to report on other events and financial statements. The filing does not contain specific details on new
• Replimune Group Files 8-K on Financials — Nov 12, 2024 Risk: medium
  Replimune Group, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing details financial statements
• Replimune Group Reports on Shareholder Vote Matters — Sep 5, 2024 Risk: low
  Replimune Group, Inc. filed an 8-K on September 5, 2024, reporting on matters submitted to a vote of security holders on September 4, 2024. The filing details t
• Replimune to Acquire Aura BioSciences for $350M — Aug 8, 2024 Risk: medium
  Replimune Group, Inc. announced on August 8, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of Aura BioSciences, Inc. f
• Replimune Group Enters Definitive Agreement, Discloses Equity Sales — Jun 13, 2024 Risk: medium
  Replimune Group, Inc. announced on June 12, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity
• Replimune Closes $300M Public Offering — Jun 6, 2024 Risk: medium
  Replimune Group, Inc. filed an 8-K on June 6, 2024, to report on the closing of its previously announced underwritten public offering. The company successfully
• Replimune Group Files 8-K with Corporate Details — Jun 3, 2024 Risk: low
  Replimune Group, Inc. filed an 8-K on June 3, 2024, reporting other events and financial statements. The filing details the company's principal executive office
• Replimune Group Files 8-K on Financials — May 16, 2024 Risk: medium
  Replimune Group, Inc. filed an 8-K on May 16, 2024, reporting on its results of operations and financial condition. The filing details financial statements and
• Replimune Appoints New CMO and CDO, Chief Medical Officer Departs — Mar 26, 2024 Risk: medium
  Replimune Group, Inc. announced on March 21, 2024, the appointment of Dr. Philip Astley-Sparke as Chief Medical Officer and Dr. Robert Burns as Chief Developmen
• Replimune Files 8-K on Financial Results & Operations — Feb 8, 2024 Risk: low
  Replimune Group, Inc. filed an 8-K on February 8, 2024, to announce its financial results and other operational updates. This filing is important for investors
• Replimune Files 8-K for Rule 425 Communications — Jan 8, 2024
  Replimune Group, Inc. filed an 8-K on January 8, 2024, to disclose that it is making written communications pursuant to Rule 425 under the Securities Act. This

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX